# Forensic Dossier: Study Forensics: Rapamycin for human longevity — promise vs proof

**Run ID:** `mechfix_study-forensics-031_Claude_Haiku_0f5db8`  
**Task:** study-forensics-031 | study_forensics | hard | study_forensics  
**Timestamp:** 2026-04-08T16:43:17.052343+00:00  
**Task Family:** mechanism_vs_evidence  
**Trap Type:** strong_preclinical_weak_human  
**Ambiguity:** medium  

## Executive Summary

**Agents tested:** Claude Haiku
**Winner:** Claude Haiku — **40.0/100** (margin: 0.0)
**Failure modes:** named_not_explained, unsupported_conclusion, wrong_answer
**Forensic flags:** 3
**Consistency findings:** 6
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Haiku | 0.0/30 | 0.0/8 | 4.8/8 | 4.8/6 | 3.9/6 | 6.0/6 | 5.6/8 | 8.0/8 | 1.5/10 | 8.5/10 | **40.0/100** |

## Study Forensics Audit

### Claude Haiku

**Classification:** `solid` [x] (gold: `mechanism_vs_evidence`)
**Finding Recall:** 100%
**Matched Findings:** mechanism_not_demonstrated, decorative_uncertainty
**Extra Findings:** cautious_scope_control, none_or_minor, conclusion_exceeds_results, correlation_as_causation

## Reasoning Integrity Audit

### Claude Haiku
**Classification:** Correct and well-supported
**Load-bearing steps:** 0 / 7

## Mechanism Analysis

### Claude Haiku
| Aspect | Status |
|--------|--------|
| Concept named | :white_check_mark: effect |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Haiku
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "solid"


## Forensic Flags

### Claude Haiku

- **[MAJOR]** `well_reasoned_wrong`: Wrong answer but structured reasoning — may have a subtle logic error
  - `final_answer`: "solid"
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "solid"
- **[MODERATE]** `ungrounded_mechanism`: Mechanism named/described but not connected to case-specific data
  - `(mechanism analysis)`: "effect"


## Evidence Map

### Claude Haiku

**Correctness:** 0.0/30
  - (+) `final_answer`: "solid"
    _Agent's answer for correctness check_
  - Note: No match (got: solid)

**Support Strength:** 0.0/8
  - (-) `final_answer`: "solid"
    _Conclusion not supported by steps_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 7
  - Note: Reasoning graph: conclusion not well grounded

**Structural Reasoning:** 4.8/8
  - (+) `steps[3]`: "4. HEDGE QUALITY CHECK: The text explicitly states 'no clinical evidence yet shows rapamycin slows aging in people' and "
    _Most informative reasoning step_
  - Note: 7 reasoning steps
  - Note: Low step utility: 0/7 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[1]`: "The human trial described is indeed the first well-designed trial in humans for this indication."
    _Most substantive assumption_
  - Note: 4/4 substantive assumptions

**Uncertainty Handling:** 3.9/6
  - (+) `uncertainties[0]`: "Whether the human trial's failure to reduce abdominal fat definitively rules out anti-aging effects (it may have other m"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.92"
    _Stated confidence level_
  - Note: 3 uncertainties (3 substantive)
  - Note: Confidence 0.92

**Alternative Hypothesis Quality:** 6.0/6
  - (+) `alternative_hypotheses[0]`: "mechanism_vs_evidence: One could argue that by mentioning enthusiasts taking rapamycin off-label, the text implicitly en"
    _Most substantive alternative hypothesis_
  - Note: 2 alternative hypotheses considered
  - Note: 2/2 include rejection reasoning

**Self Monitoring Quality:** 5.6/8
  - (+) `self_check[2]`: "Did I miss a mechanism_vs_evidence issue? The text mentions off-label use by enthusiasts, but immediately contextualizes"
    _Most substantive self-verification step_
  - Note: 5 self-check items
  - Note: Self-check quality: 0 deep, 5 arithmetic, 0 fluff

**Mechanism Quality:** 1.5/10
  - Note: Names concept but does not describe mechanism

**Communication Efficiency:** 8.5/10
  - Note: Signal density: 0.72, 650 words

**Insight Depth:** 8.0/8
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Haiku

**CRITICAL:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Answer does not match expected 'mechanism_vs_evidence'
  - `final_answer`: "solid"
  - _Impacts: correctness_

**MAJOR:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Study classification incorrect: expected 'mechanism_vs_evidence', detected 'solid'
  - `final_answer`: "solid"
  - _Impacts: correctness_

**MODERATE:**
- **Unsupported Conclusion** `[MEDIUM CONFIDENCE]`: Final answer lacks load-bearing or supporting step grounding
  - `final_answer`: "solid"
  - _Impacts: support_strength_
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Names the phenomenon but does not explain the causal mechanism
  - `final_answer`: "solid"
  - _Impacts: mechanism_quality_
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Named concept(s) ['effect'] but mechanism not described
  - _Impacts: mechanism_quality, insight_depth_


## Consistency & Grounding Audit

### Claude Haiku

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (0/11 content words)
  - `key_claims[0]`: "Mouse studies show reliable lifespan extension (10-25%, replicated) — this is strong animal evidence"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/16 content words)
  - `key_claims[1]`: "The first well-designed human trial failed its primary endpoint (abdominal fat reduction) and did no"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/12 content words)
  - `key_claims[2]`: "Expert consensus: no clinical evidence yet supports rapamycin for slowing aging in humans — this is "
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 4 has low overlap with final answer (0/6 content words)
  - `key_claims[3]`: "Off-label use carries risks — appropriate risk acknowledgment."
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 5 has low overlap with final answer (0/9 content words)
  - `key_claims[4]`: "The text does NOT claim rapamycin slows aging in humans, despite the animal evidence."
- **[WARN]** `[MEDIUM CONFIDENCE]` `mechanism_gap`: Phenomenon is named but causal mechanism is not explained
  - `final_answer`: "solid"


## Agent Profiles

### Claude Haiku (claude-haiku-4-5-20251001)
**Parse OK:** True | **Latency:** 13721ms

**Final Answer:** solid

**Confidence:** 0.92

**Assumptions:**
- The text accurately represents the mouse lifespan studies as replicated and reliable.
- The human trial described is indeed the first well-designed trial in humans for this indication.
- The primary endpoint (abdominal fat reduction) is a reasonable proxy for anti-aging benefit.
- The text's characterization of expert consensus is accurate.

**Reasoning Steps:**
1. 1. EVIDENCE TIER IDENTIFICATION: The strongest evidence presented is from animal models (mice showing 10-25% lifespan extension, replicated). The human evidence is limited: one well-designed trial with a failed primary endpoint and modest secondary outcomes, no direct aging biomarkers tested.
2. 2. CONCLUSION TIER IDENTIFICATION: The text discusses off-label human use and whether rapamycin 'slows aging in people' — this is a human therapeutic claim.
3. 3. BRIDGE GAP ANALYSIS: There is a substantial gap between animal lifespan data and human clinical evidence. The human trial failed its primary endpoint and did not measure biological aging.
4. 4. HEDGE QUALITY CHECK: The text explicitly states 'no clinical evidence yet shows rapamycin slows aging in people' and notes that 'the study did not test whether the drug slows biological aging.' These are not decorative hedges — they directly acknowledge the evidence-tier mismatch and refrain from claiming human benefit.
5. 5. CLAIM STRUCTURE: The text does NOT claim rapamycin slows aging in humans. It reports what was found (safe, failed primary endpoint, modest muscle gain) and what was NOT found (abdominal fat reduction, biological aging effects). It then reports expert caution.
6. 6. RISK ACKNOWLEDGMENT: The text mentions off-label use risks, especially for those with active cancer, showing appropriate epistemic humility about unknowns.
7. 7. OVERCLAIM CHECK: No overclaim detected. The text does not generalize mouse results to humans or claim clinical benefit without evidence.

**Key Claims:**
- Mouse studies show reliable lifespan extension (10-25%, replicated) — this is strong animal evidence.
- The first well-designed human trial failed its primary endpoint (abdominal fat reduction) and did not test biological aging — this is honest reporting of negative/inconclusive results.
- Expert consensus: no clinical evidence yet supports rapamycin for slowing aging in humans — this is an appropriate epistemic boundary.
- Off-label use carries risks — appropriate risk acknowledgment.
- The text does NOT claim rapamycin slows aging in humans, despite the animal evidence.

**Alternative Hypotheses:**
- mechanism_vs_evidence: One could argue that by mentioning enthusiasts taking rapamycin off-label, the text implicitly endorses or normalizes a practice unsupported by human evidence. However, the text frames this as a current behavior and immediately follows with expert caution, so this reading requires over-interpretation.
- correlation_vs_causation: Not applicable; the text does not claim causal relationships beyond what the studies directly tested.

**Uncertainties:**
- Whether the human trial's failure to reduce abdominal fat definitively rules out anti-aging effects (it may have other mechanisms), but the text does not claim it does — it simply reports the null result.
- Whether the modest lean muscle increase in women is clinically meaningful, but the text does not oversell it.
- The exact nature of 'biological aging' biomarkers that would be needed to test the hypothesis — but the text appropriately notes they were not measured.

**Self-Verification:**
- Did I flag a solid study as problematic? No. The text appropriately distinguishes animal from human evidence and refrains from overclaiming.
- Did I miss an overclaim? Checked: the text does not generalize mouse results to humans or claim human benefit without evidence.
- Did I miss a mechanism_vs_evidence issue? The text mentions off-label use by enthusiasts, but immediately contextualizes this with expert caution and lack of clinical evidence. The text itself does not make the mechanism_vs_evidence claim; it reports that others do and that experts disagree.
- Is the hedge language doing real work? Yes — it is not decorative. The text explicitly states what was NOT tested and what evidence is lacking, and these statements directly support the cautious conclusion.
- Did I verify the evidence-tier check? Yes. Animal evidence (tier 2) is clearly distinguished from human evidence (tier 4, limited — one trial with failed primary endpoint). The text does not bridge this gap with unsupported claims.

**Dimension Scores:**
- Correctness: 0.0/30 `..........`
- Support Strength: 0.0/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 3.9/6 `######....`
- Alternative Hypothesis Quality: 6.0/6 `##########`
- Self Monitoring Quality: 5.6/8 `#######...`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 1.5/10 `#.........`
- Communication Efficiency: 8.5/10 `########..`


## Final Verdict

**Solo run: Claude Haiku** scored **40.0/100**.

**Best per dimension:**
- Correctness: Claude Haiku (0.0/30)
- Support Strength: Claude Haiku (0.0/8)
- Structural Reasoning: Claude Haiku (4.8/8)
- Assumption Discipline: Claude Haiku (4.8/6)
- Uncertainty Handling: Claude Haiku (3.9/6)
- Alternative Hypothesis Quality: Claude Haiku (6.0/6)
- Self Monitoring Quality: Claude Haiku (5.6/8)
- Insight Depth: Claude Haiku (8.0/8)
- Mechanism Quality: Claude Haiku (1.5/10)
- Communication Efficiency: Claude Haiku (8.5/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Haiku | 13.7s | 40.0/100 | 2.9 |

Failure modes observed: named_not_explained, unsupported_conclusion, wrong_answer.
